Denali Therapeutics Inc.
Cash Flow Statement
| Line Item | FY2017 | FY2016 |
|---|---|---|
| Operating Activities | ||
| Net Income | $-88.2M | $-86.7M |
| Depreciation & Amortization | $3.1M | $1.5M |
| Depreciation | — | — |
| Amortization | — | — |
| Stock-Based Compensation | $4.4M | $3.0M |
| Net Cash from Operating Activities | $-76.6M | $-71.9M |
| Investing Activities | ||
| Capital Expenditures | $2.9M | $6.1M |
| Business Acquisitions | — | — |
| Net Cash from Investing Activities | $-41.2M | $-219.0M |
| Financing Activities | ||
| Dividends Paid | — | — |
| Stock Repurchases | — | — |
| Net Cash from Financing Activities | $296.3M | $300.5M |
| Net Change in Cash | — | — |
| Free Cash Flow | $-79.5M | $-78.0M |